NLX-112 Randomized Phase 2A Trial: Safety, Tolerability, Anti-Dyskinetic, and Anti-Parkinsonian Efficacy
NLX-112 随机 2A 期试验:安全性、耐受性、抗运动障碍和抗帕金森病疗效
期刊:Movement Disorders
影响因子:7.6
doi:10.1002/mds.30175
Svenningsson, Per; Odin, Per; Bergquist, Filip; Wirdefeldt, Karin; Nyholm, Dag; Andréasson, Mattias; Markaki, Ioanna; Johansson, Anders C; Jergil, Måns; Jankosky, Christopher; Varney, Mark A; Herbrecht, Fabienne; Johnson, Steven A; Newman-Tancredi, Adrian